• FT516 off-the-shelf NK cell cancer immuno­therapy cleared for clin­i­cal in­ves­ti­ga­tion by FDA
• Product can­di­date derived from clonal master iPSC line engi­neered with novel CD16 Fc re­cep­tor
• Clinical trial to eval­u­ate multi-dose cycles of FT516 for treat­ment of hema­to­logic malig­nancies, in­clud­ing in combi­nation with targeted anti­body ther­apy

San Diego, CA (Press Release) – Fate Thera­peutics, Inc. (NASDAQ: FATE), a clin­i­cal-stage bio­pharma­ceu­tical com­pany ded­i­cated to the devel­op­ment of pro­grammed cellular immuno­therapies for cancer and immune disorders, an­nounced to­day that the U.S. Food and Drug Admin­istra­tion (FDA) has allowed its Inves­ti­ga­tional New Drug (IND) appli­ca­tion for FT516, the Com­pany’s off-the-shelf natural killer (NK) cell prod­uct can­di­date derived from a clonal master induced pluripotent stem cell (iPSC) line engi­neered to express a novel CD16 Fc re­cep­tor. FT516 is the first-ever cell …